Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q7120261> ?p ?o }
Showing triples 1 to 49 of
49
with 100 triples per page.
- Q7120261 subject Q52333.
- Q7120261 subject Q5920511.
- Q7120261 subject Q8732555.
- Q7120261 subject Q8878420.
- Q7120261 abstract "PRC200-SS is an arylalkanolamine TRI being developed by the Mayo Clinic. Sympathomimetic PRC200-SS is the PRC050 eutomer, whereas PRC201 is the distomer. These compounds are preceded by venlafaxine, which Wyeth claims is the first SNRI. Venlafaxine was originally developed as an "opioid" although original screening returned negative results. The authors were not satisfied just to drop venlafaxine from development and continued with their study of the compounds biological activity data. Herein, they discovered that venlafaxine exerts its biological actions via interaction with the monoamine receptors. In particular, the actions of the drug on increasing the amount of 5-HT and NE were documented, although with "potentiated" analogs such as the pm-dichlorophenyl ring substituted derivative, it might be expected to behave as a SNDRI also (but no data was available to support this inference). Venlafaxine itself has been said to behave as a SNDRI at very high doses. This would be more likely to be the case in drug naїve subjects than in users that have already built up significant tolerance.Silicon containing analog of venlafaxine was prepared and demonstrated to be an active SNRI.".
- Q7120261 iupacName "(1S,2S)-3-(methylamino)-2-naphthalen-2-yl-1-phenylpropan-1-ol".
- Q7120261 pubchem "20631904".
- Q7120261 thumbnail PRC200_structure.png?width=300.
- Q7120261 wikiPageWikiLink Q10850.
- Q7120261 wikiPageWikiLink Q1130172.
- Q7120261 wikiPageWikiLink Q1229520.
- Q7120261 wikiPageWikiLink Q14865372.
- Q7120261 wikiPageWikiLink Q161519.
- Q7120261 wikiPageWikiLink Q167934.
- Q7120261 wikiPageWikiLink Q17166125.
- Q7120261 wikiPageWikiLink Q2273909.
- Q7120261 wikiPageWikiLink Q2914731.
- Q7120261 wikiPageWikiLink Q301676.
- Q7120261 wikiPageWikiLink Q411418.
- Q7120261 wikiPageWikiLink Q412982.
- Q7120261 wikiPageWikiLink Q420.
- Q7120261 wikiPageWikiLink Q423288.
- Q7120261 wikiPageWikiLink Q452419.
- Q7120261 wikiPageWikiLink Q4634071.
- Q7120261 wikiPageWikiLink Q52333.
- Q7120261 wikiPageWikiLink Q58396.
- Q7120261 wikiPageWikiLink Q58397.
- Q7120261 wikiPageWikiLink Q5920511.
- Q7120261 wikiPageWikiLink Q598405.
- Q7120261 wikiPageWikiLink Q61387.
- Q7120261 wikiPageWikiLink Q670.
- Q7120261 wikiPageWikiLink Q7120261.
- Q7120261 wikiPageWikiLink Q7180298.
- Q7120261 wikiPageWikiLink Q79899.
- Q7120261 wikiPageWikiLink Q8732555.
- Q7120261 wikiPageWikiLink Q8878420.
- Q7120261 wikiPageWikiLink Q898407.
- Q7120261 wikiPageWikiLink Q901932.
- Q7120261 wikiPageWikiLink Q903566.
- Q7120261 iupacName "-3".
- Q7120261 pubchem "20631904".
- Q7120261 type ChemicalSubstance.
- Q7120261 type Drug.
- Q7120261 type ChemicalObject.
- Q7120261 type Thing.
- Q7120261 type Q8386.
- Q7120261 comment "PRC200-SS is an arylalkanolamine TRI being developed by the Mayo Clinic. Sympathomimetic PRC200-SS is the PRC050 eutomer, whereas PRC201 is the distomer. These compounds are preceded by venlafaxine, which Wyeth claims is the first SNRI. Venlafaxine was originally developed as an "opioid" although original screening returned negative results. The authors were not satisfied just to drop venlafaxine from development and continued with their study of the compounds biological activity data.".
- Q7120261 label "PRC200".
- Q7120261 depiction PRC200_structure.png.